Combination Adjuvants Enhance Recombinant H5 Hemagglutinin Vaccine Protection Against High-Dose Viral Challenge in Chickens.

IF 5.2 3区医学 Q1 IMMUNOLOGY

Vaccines Pub Date : 2024-12-23 DOI:10.3390/vaccines12121448

Yanjuan He, Jiaxin Wang, Lanyan Chi, Yajing Dong, Huixin Chen, Xiaocui Meng, Ming Liao, Yongwen Luo, Huiying Fan

{"title":"Combination Adjuvants Enhance Recombinant H5 Hemagglutinin Vaccine Protection Against High-Dose Viral Challenge in Chickens.","authors":"Yanjuan He, Jiaxin Wang, Lanyan Chi, Yajing Dong, Huixin Chen, Xiaocui Meng, Ming Liao, Yongwen Luo, Huiying Fan","doi":"10.3390/vaccines12121448","DOIUrl":null,"url":null,"abstract":"Background: Recombinant avian influenza subunit vaccines often require adjuvants to enhance immune responses. This study aims to evaluate the immune-enhancing potential of seven combination adjuvants in specific pathogen-free (SPF) chickens.Methods: SPF chickens were vaccinated with combinations of ISA78VG and adjuvants, including Quil-A, CpG, and monophosphoryl lipid A (MPLA). Their immune responses were assessed using a vaccination and viral challenge protection model.Results: The combinations of ISA78VG with Quil-A, CpG&MPLA or CpG&Quil-A significantly enhanced antibody responses and provided cross-protection against the H5N8-20135 strain. The ISA78VG&MPLA and ISA78VG&CpG&MPLA combinations induced the stronger IFN-γ production, with CpG further amplifying the immune response. The ISA78VG&Quil-A formulation, in particular, stimulated rapid antibody responses, achieving a 100% seroconversion by day 14 and high titers of hemagglutination inhibition (HI) antibodies against both the recombinant HA antigen and the H5N6-20053 virus.Conclusions: The ISA78VG&Quil-A combination is an ideal adjuvant for enhancing the immunogenicity of avian influenza rHA subunit vaccines, offering a promising strategy for H5 subtype vaccine development.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"12 12","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680309/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12121448","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recombinant avian influenza subunit vaccines often require adjuvants to enhance immune responses. This study aims to evaluate the immune-enhancing potential of seven combination adjuvants in specific pathogen-free (SPF) chickens.

Methods: SPF chickens were vaccinated with combinations of ISA78VG and adjuvants, including Quil-A, CpG, and monophosphoryl lipid A (MPLA). Their immune responses were assessed using a vaccination and viral challenge protection model.

Results: The combinations of ISA78VG with Quil-A, CpG&MPLA or CpG&Quil-A significantly enhanced antibody responses and provided cross-protection against the H5N8-20135 strain. The ISA78VG&MPLA and ISA78VG&CpG&MPLA combinations induced the stronger IFN-γ production, with CpG further amplifying the immune response. The ISA78VG&Quil-A formulation, in particular, stimulated rapid antibody responses, achieving a 100% seroconversion by day 14 and high titers of hemagglutination inhibition (HI) antibodies against both the recombinant HA antigen and the H5N6-20053 virus.

Conclusions: The ISA78VG&Quil-A combination is an ideal adjuvant for enhancing the immunogenicity of avian influenza rHA subunit vaccines, offering a promising strategy for H5 subtype vaccine development.

查看原文本刊更多论文

联合佐剂增强重组H5血凝素疫苗对鸡大剂量病毒攻击的保护作用。

背景：重组禽流感亚单位疫苗通常需要佐剂来增强免疫反应。本研究旨在评价7种联合佐剂对SPF鸡的免疫增强作用。方法：用ISA78VG和Quil-A、CpG、单磷酰脂质A （MPLA）等佐剂联合接种SPF级鸡。使用疫苗接种和病毒攻击保护模型评估他们的免疫反应。结果：ISA78VG与Quil-A、CpG&MPLA或CpG&Quil-A联合使用可显著增强抗体应答，并对H5N8-20135株具有交叉保护作用。ISA78VG&MPLA和ISA78VG&CpG&MPLA组合诱导了更强的IFN-γ产生，CpG进一步放大了免疫反应。特别是ISA78VG&Quil-A制剂，刺激了快速的抗体反应，在第14天实现了100%的血清转化，并且针对重组HA抗原和H5N6-20053病毒产生了高滴度的血凝抑制（HI）抗体。结论：ISA78VG&Quil-A组合是一种理想的增强禽流感rHA亚单位疫苗免疫原性的佐剂，为H5亚型疫苗的开发提供了一种有前景的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

8.90

自引率

16.70%

发文量

1853

审稿时长

18.06 days

期刊介绍： Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.